Total
0
Shares
CEO, Rod Matheson Source: marvelbiotechnology.com
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Marvel Biosciences Corp. (MRVL) reports a successful process development of the active pharmaceutical ingredient of its lead drug MB-204
  • The development is being done by its subsidiary, Marvel Biotechnology Inc. and now enters an important milestone of engineering and current good manufacturing practices run of its multi-kilogram batches of the drug
  • The run will provide Marvel Biotechnology with a batch of its lead drug candidate that can be used in good laboratory practise toxicology studies
  • MB-204 is being developed for neurological conditions such as depression, anxiety, ADHD and Alzheimer’s
  • Marvel Biosciences Corp. (MRVL) is up 8.7 per cent and is trading at $0.25 per share at 2:34 p.m. ET

Marvel Biosciences Corp. (MRVL) reports a successful process development of the active pharmaceutical ingredient of its lead drug MB-204.

The development is being done by its subsidiary, Marvel Biotechnology Inc. It now enters an important milestone of engineering and current good manufacturing practices run of its multi-kilogram batches of the drug.

The batches will be done in partnership with Zhejiang Ausun Pharmaceutical Co., Ltd.

The run will provide Marvel Biotechnology with a batch of its lead drug candidate that can be used in good laboratory practice toxicology studies.

It is scheduled to begin in Marvel Biotechnology’s Q4, 2021.

Zhejiang Ausun will be providing the company with a batch that ensures the identity, quality and purity in preparation for entering its phase I clinical studies in 2022.

Rod Matheson, CEO of Marvel Biotechnology, comments the on efficacy and safety the MB-204 drug can provide.

“With the partnership we have in place with Ausun, we have now entered a key and very important stage in the development of MB-204 to drive this asset into clinical studies,” he said.

“These milestones are key in further advancing our discussions with potential commercial partners to ensure the best outcome for our shareholders.”

MB-204 is being developed for neurological conditions such as depression, anxiety, ADHD and Alzheimer’s.

Marvel Biotechnology’s compound is a novel patented fluorinated derivative of the US-FDA-approved Parkinson’s disease drug Istradefylline (Nourianz®).

Both Istradefylline and MB-204 are highly active derivatives of caffeine, which can help to reduce the risk of developing Parkinson’s and Alzheimer’s disease.

Marvel Biosciences Corp. (MRVL) is up 8.7 per cent and is trading at $0.25 per share at 2:34 p.m. ET.

More From The Market Herald
BioMark Diagnostics - Founder and CEO, Rashid Bux

" BioMark (CSE:BUX) to collaborate with AstraZeneca and Pfizer Canada to improve early detection of lung cancer

BioMark Diagnostics (BUX) will participate in a research project that aims to enhance the efficiency of lung cancer screening programs.

" Algernon Pharmaceuticals (CSE:AGN) welcomes new CFO

Algernon Pharmaceuticals (AGN) has appointed Mr. James Kinley as the Chief Financial Officer (CFO), effective December 1, 2021.

" Beyond Medical Technologies (CSE:DOCT) ramps up mask manufacturing in response to new South African variant

Beyond Medical Technologies (DOCT) subsidiary Micron Technologies has been manufacturing medical masks in British Columbia since August 2020.

" Sun Life Financial (TSX:SLF) partners with CloudMD (TSXV:DOC)

Sun Life (SLF) has partnered with CloudMD (DOC) to add its Mental Health Coach solution to group benefits plans.